8-K: Oncology Institute Names RadNet CFO Mark Stolper to Board

The Oncology Institute, Inc. announced the appointment of Mark D. Stolper, current CFO of RadNet, Inc., to its Board of Directors, effective January 2, 2026.

Summary

• The Oncology Institute, Inc. (TOI) appointed Mark D. Stolper to its Board of Directors, effective January 2, 2026.
• Mr. Stolper will serve as the Audit Committee Chairman and has been designated as the Audit Committee financial expert.
• He brings significant public company experience, currently serving as CFO of RadNet, Inc. (NASDAQ: RDNT) since 2004, and previously held board positions at Envision Healthcare and 21st Century Oncology Holdings, Inc.
• His compensation includes $75,000 per annum, paid quarterly, and restricted stock unit awards to be granted at a later date.
• The appointment was announced via a press release on January 5, 2026.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced and qualified financial expert to the board, particularly as Audit Committee Chairman, is a strong positive for corporate governance and strategic financial planning. This strengthens the company's leadership and oversight capabilities.

Positives

• Appointment of a highly experienced financial expert, Mark D. Stolper, to the Board of Directors.
• Mr. Stolper's background as CFO of a public company (RadNet, Inc.) and board experience in the healthcare/oncology sector (Envision Healthcare, 21st Century Oncology) brings valuable expertise in capital markets, financial planning, and payor strategy.
• His role as Audit Committee Chairman and designated financial expert strengthens corporate governance and financial oversight.
• The appointment meets Nasdaq independence requirements, enhancing board independence.

Future Outlook

Management believes Mr. Stolper's expertise will be invaluable in TOI's next phase of growth, and Mr. Stolper expressed excitement about TOI's mission and its strong position for continued growth and success in upcoming years.

Management Comments

• "We are ecstatic to have a seasoned public company CFO like Mark join our board. Mark brings tremendous experience in capital markets, financial planning and payor strategy that will be invaluable to TOI in our next phase of growth." Anne McGeorge, Chairman of the Board of TOI.
• "I couldn't be more excited to join TOI as a board member. TOI's mission to address the financial toxicity of cancer care while empowering patients is critically important at this time in healthcare, and I believe they are well poised for continued growth and success in upcoming years." Mark Stolper.

Industry Context

The appointment of a seasoned financial executive with deep experience in public company finance and the oncology space underscores the increasing complexity and financial demands within the value-based cancer care sector. As healthcare models shift towards value-based care, expertise in capital markets and payor strategy becomes crucial for growth and sustainability, aligning with TOI's mission to address the financial toxicity of cancer care.

Comparison to Industry Standards

• Mark Stolper's experience as CFO of RadNet, Inc. (NASDAQ: RDNT), a publicly traded diagnostic imaging services company, provides a strong benchmark for financial leadership in a healthcare services context.
• His previous board roles at Envision Healthcare and 21st Century Oncology Holdings, Inc. demonstrate direct experience with large-scale healthcare provider organizations, including those in the oncology sector, which is directly comparable to TOI's operations.
• The appointment of an independent director who also serves as Audit Committee Chairman and financial expert aligns with best practices in corporate governance for publicly traded companies, particularly those listed on Nasdaq.

Management Changes

Corporate Governance

Related Party Transactions

• No arrangements or understandings between Mr. Stolper and any other person pursuant to which he was selected or appointed a director, nor are there any transactions between Mr. Stolper and the Company that would be reportable under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Enhanced corporate governance and financial oversight through the appointment of an experienced financial expert to the board and as Audit Committee Chairman, potentially leading to improved financial reporting and strategic decision-making.
• Management: Gains a seasoned executive with expertise in capital markets, financial planning, and payor strategy to support the company's growth phase.
• Patients/Customers: Indirectly benefits from strengthened leadership and strategic direction, supporting the company's mission of value-based cancer care.

Next Steps

• Mr. Stolper's term as a director will expire at the Company's next annual meeting of stockholders.
• It is expected that Mr. Stolper will be nominated as part of management's slate of director nominees at the next annual meeting.
• Restricted stock unit awards for Mr. Stolper's service will be granted at a later date.

Key Dates

Recommendation

The appointment of Mark D. Stolper, a highly experienced public company CFO and healthcare board member, to The Oncology Institute's Board of Directors and as Audit Committee Chairman is a significant positive for corporate governance and financial oversight. This move strengthens the board's expertise in capital markets and payor strategy, which is crucial for the company's stated 'next phase of growth' in value-based oncology. However, this is a governance enhancement rather than a direct operational or financial performance update. While it improves the company's foundational strength, it does not immediately alter the investment thesis regarding operational performance or market position, thus warranting a 'hold' recommendation for existing investors, while new investors should consider this a positive factor in their broader due diligence.

Keywords

The Oncology Institute, TOI, Board of Directors, Director Appointment, Mark Stolper, Audit Committee, Financial Expert, Corporate Governance, Healthcare, Oncology, RadNet, RDNT, Value-Based Care